Jones Trading Reaffirms “Hold” Rating for Mural Oncology (NASDAQ:MURA)

Mural Oncology (NASDAQ:MURA)‘s stock had its “hold” rating reiterated by Jones Trading in a research report issued on Tuesday,Benzinga reports.

Separately, HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Mural Oncology in a research report on Wednesday, March 12th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $13.00.

Mural Oncology Stock Performance

MURA stock opened at $1.33 on Tuesday. The firm has a 50 day moving average price of $3.82 and a 200-day moving average price of $3.60. Mural Oncology has a 52-week low of $1.30 and a 52-week high of $5.12. The firm has a market capitalization of $22.91 million, a price-to-earnings ratio of -0.15 and a beta of 3.66.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($2.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same quarter in the prior year, the company earned ($3.57) earnings per share. As a group, sell-side analysts forecast that Mural Oncology will post -7.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Commerce Bank bought a new position in Mural Oncology during the 3rd quarter valued at about $39,000. FMR LLC raised its holdings in shares of Mural Oncology by 124.7% during the third quarter. FMR LLC now owns 20,580 shares of the company’s stock valued at $64,000 after purchasing an additional 11,423 shares during the last quarter. Jane Street Group LLC bought a new position in Mural Oncology during the fourth quarter valued at approximately $68,000. Two Sigma Advisers LP bought a new position in Mural Oncology during the fourth quarter valued at approximately $84,000. Finally, Bridgeway Capital Management LLC purchased a new stake in Mural Oncology in the fourth quarter worth approximately $94,000. 80.21% of the stock is owned by institutional investors.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.